Login to Your Account



Chiesi snags Atopix in potential $80M milestone-based deal

By Nuala Moran
Staff Writer

Monday, November 21, 2016

LONDON – U.K. allergy specialist Atopix Therapeutics Ltd. is being acquired by the privately held  Chiesi Farmaceutica SpA, in a milestone-based deal that could exceed €75 million.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription